Frazier Life Sciences announced Thursday that it raised $1.3 billion for its 12th fund — its largest to date — to back more biopharmaceutical startups.
- Frazier Life Sciences, which focuses on investing and creating early stage biotech and therapeutics companies, raised $987 million for its previous venture fund. It also has a separate fund for small- and mid-cap public biotech companies.
- Frazier, which backed Seattle-based Alpine Immune Sciences (acquired last year by Vertex for $4.9 billion) has raised more than $3.6 billion across five venture funds since 2016, and $1.7 billion in public funds since 2021.
- The firm is based in Silicon Valley and has offices in San Diego, Seattle, and Boston. Frazier also operates a healthcare arm, Frazier Healthcare Partners, that is based in Seattle and raised $2.3 billion for its 11th fund last year.
Previously: AI will transform parts of healthcare — but slow adoption and sales cycles could impede startups
